skip to main content
Harris Beach Murtha Attorneys at Law
Capabilities
People
main menu
Harris Beach Murtha Attorneys at Law
  • Capabilities
  • People
  • Capabilities
  • People
About
About
Inclusion and Engagement
Social Impact
Lateral Opportunities
About
Inclusion and Engagement
Social Impact
Lateral Opportunities
Resources
Insights
News
Events
Insights
News
Events
Careers
Contact
Offices
In The News
October 19, 2026

Firm Attorneys Appear in DRI’s For the Defense Magazine

Authors and Contacts

Kelly Jones Howell

Jesse C. Wang

Marina Plotkin

Facebook
(Twitter)
LinkedIn
Email
Copy Page Link

Three members of the firm’s Medical and Life Sciences Practice Group recently wrote a column examining the scope of OTC preemption and a shift toward defense-favorable decisions that was published in a magazine targeting defense, insurance and corporate counsel.

Kelly Jones Howell, Marina Plotkin and Jesse C. Wang discussed federal preemption as a defense against state-law claims involving over-the-counter drugs, particularly lawsuits alleging misleading labeling or undisclosed trace contaminants. “Where Federal Regulation Stops and Tort Law Begins” appeared on pages 22 to 27 in DRI’s For the Defense Magazine.

The three looked at recent decisions, such as Monsanto Co. v. Durnell, involving Roundup weed killer and concluded federal law provides broad protection, prior enforcement of the FCDA is restricted, the type of damages claimed are critical, scientific detection does not automatically establish liability, courts have applied the statute inconsistently and recent decisions favor a more textual approach.

“For defense counsel, Durnell and the recent OTC decisions serve as a reminder to press § 379r’s text at every stage, anchor arguments in monograph compliance, and criticize repackaged labeling challenges directly, rather than assuming courts will apply the statute correctly on their own. For plaintiffs’ counsel, the same decisions narrow the available paths forward, but do not close them off entirely. Personal-injury claims grounded in genuine product liability theories, like Rutledge, remain viable at the motion to dismiss stage. Ultimately, Section 379r reflects that OTC drug labeling should be governed by uniform federal standards rather than a patchwork of state requirements. While courts have not always applied that principle consistently, an increasing number of decisions are enforcing the statute as written.”

Kelly had previously written a legal alert on Monsanto Co. v. Durnell, and a legal alert on a similar preemption case, L’Oréal USA Benzoyl Peroxide Products Litigation.

Read the entire column in For the Defense Magazine for complete details.

Authors and Contacts

Partner Kelly Jones Howell

Kelly Jones Howell

Member

Marina Plotkin

Marina Plotkin

Member

Jesse Wang

Jesse C. Wang

Associate

Related Legal Practices

Medical and Life Sciences

Related Focuses

Pharmacy Law
Facebook
(Twitter)
LinkedIn
Email
Copy Page Link

Contact Us

Harris Beach Murtha Attorneys at Law
  • Contact
  • Offices
  • Privacy Policy
  • Legal Disclaimer
  • Site Map
  • Contact
  • Offices
  • Privacy Policy
  • Legal Disclaimer
  • Site Map
Payment Portal
X-twitter Facebook Linkedin Instagram

Attorney Advertising. Prior results do not guarantee a similar outcome. © 2025 Harris Beach Murtha Cullina PLLC

TRUSTe
Harris Beach Murtha Attorneys at Law
Back to Top

News

Firm Attorneys Appear in DRI’s For the Defense Magazine

Capabilities
People
Harris Beach Murtha Attorneys at Law
In The News
October 19, 2026

Firm Attorneys Appear in DRI’s For the Defense Magazine

News

Three members of the firm’s Medical and Life Sciences Practice Group recently wrote a column examining the scope of OTC preemption and a shift toward defense-favorable decisions that was published in a magazine targeting defense, insurance and corporate counsel.

Kelly Jones Howell, Marina Plotkin and Jesse C. Wang discussed federal preemption as a defense against state-law claims involving over-the-counter drugs, particularly lawsuits alleging misleading labeling or undisclosed trace contaminants. “Where Federal Regulation Stops and Tort Law Begins” appeared on pages 22 to 27 in DRI’s For the Defense Magazine.

The three looked at recent decisions, such as Monsanto Co. v. Durnell, involving Roundup weed killer and concluded federal law provides broad protection, prior enforcement of the FCDA is restricted, the type of damages claimed are critical, scientific detection does not automatically establish liability, courts have applied the statute inconsistently and recent decisions favor a more textual approach.

“For defense counsel, Durnell and the recent OTC decisions serve as a reminder to press § 379r’s text at every stage, anchor arguments in monograph compliance, and criticize repackaged labeling challenges directly, rather than assuming courts will apply the statute correctly on their own. For plaintiffs’ counsel, the same decisions narrow the available paths forward, but do not close them off entirely. Personal-injury claims grounded in genuine product liability theories, like Rutledge, remain viable at the motion to dismiss stage. Ultimately, Section 379r reflects that OTC drug labeling should be governed by uniform federal standards rather than a patchwork of state requirements. While courts have not always applied that principle consistently, an increasing number of decisions are enforcing the statute as written.”

Kelly had previously written a legal alert on Monsanto Co. v. Durnell, and a legal alert on a similar preemption case, L’Oréal USA Benzoyl Peroxide Products Litigation.

Read the entire column in For the Defense Magazine for complete details.

Authors

Kelly Jones Howell

Member
(212) 912-3652
khowell@harrisbeachmurtha.com

Marina Plotkin

Member
(212) 313-5409
mplotkin@harrisbeachmurtha.com

Jesse C. Wang

Associate
(212) 912-3570
jcwang@harrisbeachmurtha.com
Attorney Advertising. Prior results do not guarantee a similar outcome. © 2026 Harris Beach Murtha Cullina PLLC
Content current as of October 25, 2026 8:30 am